Search Results - Shiwei Tu

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles

    SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles by Ting Zhang, Jianyan Xu, Junzhao Yin, Yun Gao, Hanwen Zheng, Beibei Fu, Jiakang Sun, Zhibin Xu, Shiwei Tu, Yuchang Mao, Weiyun Wen, Bolei Qu, Lingfeng You, Zhendong Xue, Xing Sun, Dan Cao, Jun Feng, Min Hu, Feng He

    Published 2025-01-01 Get full text
    Article

    Save to List
    Saved in:
  2. 2
    SHR-A1811, a novel anti-HER2 antibody-drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles.

    SHR-A1811, a novel anti-HER2 antibody-drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. by Ting Zhang, Jianyan Xu, Junzhao Yin, Yun Gao, Hanwen Zheng, Beibei Fu, Jiakang Sun, Zhibin Xu, Shiwei Tu, Yuchang Mao, Weiyun Wen, Bolei Qu, Lingfeng You, Zhendong Xue, Xing Sun, Dan Cao, Jun Feng, Min Hu, Feng He

    Published 2025-01-01

    HER2-targeting antibody-drug conjugates (ADCs), especially trastuzumab deruxtecan (T-DXd), have revolutionized the treatment landscape of HER2-expressing or mutant cancers. However, undesired adverse events are still inevitable and it is necessary to discover a HER2-directed ADC with better safety p...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: